Myovant Sciences Rejects $2.5 Bln Offer From Sumitovant And Sumitomo Pharma

Myovant Sciences Ltd. (MYOV) rejected a $2.5 billion takeover offer from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd saying that the offer undervalues the company.

Myovant Sciences confirmed that it received a preliminary, non-binding proposal from Sumitovant Biopharma and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash. Sumitovant currently holds about 52% of the outstanding shares of the company.

Myovant said its Special Committee determined that the offer significantly undervalues the company and, therefore, is not in the best interests of the company or its minority shareholders.

The Special Committee remains open to considering any improved proposal that reflects the full and fair value of the company and is otherwise in the best interests of the company and its shareholders, and is prepared to engage further with Sumitomo regarding any such proposal, Myovant said in a statement.

In a separate press release, Sumitomo Pharma said the proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange (NYSE).

According to Sumitomo Pharma, the proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion. The proposed per share consideration represents a premium of about 27% to Myovant's closing share price on September 30, 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream Amazon.com Inc. plans to spend more than $1 billion annually to produce movies that will get a theatrical release, Bloomberg reported, citing people familiar with the matter. The online retailer giant, which acquired movie maker MGM Studios earlier this year for $8.45 billion, is likely to produce between 12 and 15 movies each year for movie theaters. New York-based Bentex Group has recalled various children's clothing sets due to violation of the federal lead paint and lead content ban, as well as lead poisoning risk, the U.S. Consumer Product Safety Commission said. The recall involves about 87,000 units of Bentex children's clothing sets in nine different Disney themed styles.
Follow RTT